When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ONCY - Dosing underway in Oncolytics Bio/Incyte IRENE study in breast cancer
Oncolytics Biotech Inc.
Oncolytics Biotech (NASDAQ:ONCY) has dosed first patient in Phase 2 IRENE study of Company's pelareorep in combination with Incyte's (NASDAQ:INCY) anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012) in unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).
More news on: Oncolytics Biotech Inc., Incyte Corporation, Healthcare stocks news,